Lakewood-Amedex Biotherapeutics CEO Issues Letter to Shareholders Highlighting Transformational Progress and Outlook for Nu-3

Lakewood-Amedex Biotherapeutics listed on Nasdaq as LABT and raised $7.5 million through a Series C preferred-stock private placement to fund planned Phase 2a development of Nu-3 for infected diabetic foot ulcers. Positive preclinical safety data supported testing 2%, 5% and 10% Nu-3 doses, while the company expanded its IP estate to 72 granted patents and 29 pending applications. Investors face potential dilution: 451,240 Series C preferred shares remain outstanding and could convert into up to 4.51 million common shares; shareholders are also being asked to authorize an increase in common shares to 100 million and a potential reverse split of up to 1-for-20.

Analysis

LABT is a financing-structure trade, not yet a clinical-data trade. The remaining variable-price preferred is economically equivalent to a controlled equity-distribution program: conversion at a discount to recent trading prices gives the holder incentive to sell into liquidity, while the 4.99% ownership cap merely staggers rather than eliminates the overhang. The registered maximum of 4.51 million common shares is material against the current authorized-share base, and the proposed expansion to 100 million shares removes a near-term constraint on future dilution.

The immediate catalyst is the September 22 shareholder vote and subsequent conversion/sale disclosures; these are more likely to govern the next 1-3 months than preclinical claims or advisor appointments. A reverse-split authorization, even if described as contingent, increases the probability of a future financing/listing-maintenance loop: price weakness prompts a split, which can restore nominal compliance but rarely fixes cash runway. Clinical initiation is only a de-risking operational milestone; the meaningful valuation inflection is human efficacy and wound-healing data, likely a 6-18 month event depending on enrollment.

Consensus retail attention may focus on a cleaner balance sheet and antimicrobial-platform optionality, but the relevant question is whether cash covers trial completion without another raise. Until management discloses quarterly cash burn, expected Phase 2a enrollment/sites, primary endpoint, and an explicit data timeline, the platform's patent count has little bearing on near-term equity value. Comparable wound-care and anti-infective developers with human proof-of-concept can command sharply higher valuations, but preclinical antimicrobial activity has a poor translation record in polymicrobial chronic wounds.

NDAQ has no fundamental read-through beyond marginal listing-fee revenue, and BCS has no identifiable economic linkage from the supplied information. There is no basis for a sympathetic trade in either name. The actionable signal is LABT-specific liquidity and dilution, with upside reserved for confirmation that the preferred overhang is fully retired and that the trial is funded through a defined data catalyst.

Key Decisions for Investors

• Avoid initiating a directional LABT long before the remaining preferred converts. Monitor weekly volume, Form 4/13D-style ownership disclosures, and outstanding-share updates; reassess only after the preferred balance reaches zero and the stock absorbs the associated supply for 2-3 weeks.
• For a tactical short, use a small, borrow-permitting LABT position only on liquidity-driven rallies around the shareholder vote or trial-initiation publicity. Cover if the preferred is fully converted, cash runway is explicitly guided through Phase 2a data, or the stock holds above the post-rally high on materially elevated volume; micro-cap borrow and squeeze risk make this unsuitable for size.
• Set a clinical watch trigger rather than underwriting Phase 2 upside today: require protocol disclosure showing a credible efficacy endpoint, sufficient sample size, enrollment duration, and cash resources through readout. A funded, initiated trial with a dated 6-12 month data window would justify revisiting a catalyst long.
• Treat authorization of 100 million shares or a reverse split as a negative governance/liquidity signal unless paired with a clearly accretive financing or strategic transaction. A post-vote decline accompanied by increased conversion volume would validate the dilution thesis; rejection of the proposal could instead create immediate Nasdaq-compliance and financing risk.